Analyses of metabolomics and proteomics in breast cancer sub-types

• Research type

  Research Study

• Full title

  Analyses of metabolomics and proteomics in breast cancer using tissue samples and serum of newly diagnosed breast cancer patients to develop better biochemical understanding of all phenotypes of breast cancer but with a specific interest in triple negative sub-phenotypes.

• IRAS ID

  304306

• Contact name

  Nicholas Rattray

• Contact email

  nicholas.rattray@strath.ac.uk

• Sponsor organisation

  University of Strathclyde

• Duration of Study in the UK

  2 years, 0 months, 0 days

• Research summary

  Patients diagnosed with breast cancer can vary considerably in their response to current treatment and in their subsequent prognosis. This variation is likely to be linked to the classification of breast cancer phenotypes and sub-phenotypes ( these are the different characteristics of breast cancers based on various aspects of their pathology). Current methods of classification have been used to develop breast cancer treatment and in predicting outcome of treatment. However, these conventional pathological markers are limited in predicting patient response to therapeutic interventions. There is a need to develop more patient specific levels of stratification for all breast cancer types which will lead to more precise drug regimens and better clinical outcomes for patients.
  The aim of this project is to investigate if multiplexed metabolomics and proteomics analyses ( examining the individual chemical and biological molecules of a patients cancer)can be used to develop better biomolecular understanding of breast cancer phenotypes. The project aims to look at all breast cancer types but analyse additional tissue from a specific sub-group of breast cancers termed the triple negative breast cancer sub-phenotypes. These tumours are often more limited in treatment options and more varied in response to conventional treatment. This information would help develop new and varied drug treatments for breast cancer.

• REC name

  Wales REC 7

• REC reference

  23/WA/0096

• Date of REC Opinion

  14 Mar 2023

• REC opinion

  Favourable Opinion